Prescription Drug Pricing Trends and Policy Changes

Drug prices fell for third straight month (0.8% in July). Trump policies (TrumpRx, GLP-1 bridge program) credited with steepest decline in 60+ years. MFN pricing debate continues with AARP report showing $200B savings potential. PBM transparency initiatives (TrumpRx, Delaware reforms) are gaining traction. Generic tariff proposal could reshape supply chain.